Literature DB >> 33595131

Bisphosphonate nephropathy: a case series and review of the literature.

Camiel de Roij van Zuijdewijn1,2, Wim van Dorp1, Sandrine Florquin3, Joris Roelofs3, Kees Verburgh1.   

Abstract

From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis (FSGS). Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  FSGS; bisphosphonate; mevalonate pathway; nephropathy; pamidronate; tubular toxicity; zoledronate

Year:  2021        PMID: 33595131     DOI: 10.1111/bcp.14780

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  2 in total

1.  Multimodal regulation of the osteoclastogenesis process by secreted group IIA phospholipase A2.

Authors:  Maria Mangini; Rosa D'Angelo; Caterina Vinciguerra; Christine Payré; Gérard Lambeau; Barbara Balestrieri; Julia F Charles; Stefania Mariggiò
Journal:  Front Cell Dev Biol       Date:  2022-08-29

Review 2.  The Role of Extracellular Vesicles in Osteoporosis: A Scoping Review.

Authors:  Weifei Zhang; Pengzhou Huang; Jianjing Lin; Hui Zeng
Journal:  Membranes (Basel)       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.